A retrospective cohort study reported that the CAR-HEMATOTOX score predicts severe neutropenia and thrombocytopenia after CAR-T cell therapy, using data from 96 patients. The analysis described dramatically higher rates of both complications in higher-risk groups. The work suggests CAR-HEMATOTOX can help clinicians anticipate hematologic toxicity during the post-infusion period, potentially supporting earlier interventions and closer monitoring plans. For CAR-T operators and clinicians, the key operational value is that a risk score could improve resource planning and reduce preventable morbidity associated with severe blood count crashes.